Published: May, 2018
The global hematological malignance market is highly competitive in nature with a large number of players operating in it worldwide, states a new research study by Transparency Market Research. In 2015, the leading four players in the market accounted for more than 58% share of the global market and is likely to remain in the similar leading position throughout the forecast period. To expand their product horizon, these players are focusing on extending their products and services in developing economies, which is likely to accelerate the growth of the overall market in the coming years. Some of the key players that are operating in the global hematological malignances market are Roche, Celgene, Novartis, and AbbVie, The rising number of mergers and acquisitions are estimated to encourage the growth of the overall market in the next few years.
As per the market research report by Transparency Market Research, in 2015, the global hematological malignance was worth US$27.4 bn. This market is likely to reach a value of US$51.9 bn by the end of 2024. The market is projected to register a healthy 7.50% CAGR between 2016 and 2024.
North America to Lead Global Hematological Malignances Market
Among the key regional segments, North America is projected to experience a high growth throughout the forecast period. The increasing prevalence of hematological cancers and the advanced diagnostic technologies are some of the key factors that are estimated to encourage the growth of the North America market in the next few years. In addition to this, the presence of a large number of players is considered to generate promising growth opportunities in the coming years. This region is expected to be closely followed by Europe in the coming years, thanks to the increasing awareness among people regarding hematological malignance. Furthermore, Asia Pacific is estimated to witness significant growth throughout the forecast period.
Targeted therapy, immunotherapy, and chemotherapy are the major treatment methods in the global hematological malignances market. Among these segments, immunotherapy held a large share in 2015, and is expected to remain in the leading position throughout the forecast period. The high efficiency of immunotherapy and the less number of side effects are the key factors that are projected to accelerate the growth of this segment in the next few years.
Rising Number Lifestyle Disorders to Encourage Market Growth
The unhealthy and sedentary lifestyle of people worldwide resulting in a number of lifestyle-related disorders is considered as a major factor estimated to accelerate the growth of the global market in the next few years. The rising focus on research and development activities and innovations in the field of healthcare sector is projected to accelerate the growth of the global hematological malignances market in the coming few years. In addition to this, the rising awareness among consumers concerning the availability of advanced treatments is projected to generate promising growth opportunities for the market players in the next few years.
On the flip side, the high cost of branded drugs and the lack of favorable reimbursements policies are some of the key factors that are likely to restrict the overall growth of the global hematological malignances market in the coming few years.
This information is based on the findings of a research report published by Transparency Market Research (TMR), titled “Hematological Malignancies Market (Disease Condition - Leukemia, Lymphoma, and Myeloma; Therapy – Chemotherapy, Immunotherapy, and Targeted Therapy; Distribution Channel - Hospital Pharmacies, Medical Stores, and E-commerce Platform) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”
- Rising chronic and lifestyle disorders to encourage growth of the global hematological malignance market in the next few years.
- North America and Europe to witness high growth with the presence of large number of players in the forecast period.
The global hematological malignances market has been segmented as below:
Global Hematological Malignances Market, by Disease Condition
Global Hematological Malignances Market, by Therapy
- Targeted Therapy
Global Hematological Malignances Market, by Distribution Channel
- Hospital Pharmacies
- Medical Stores
- E-commerce Platform
Global Hematological Malignances Market, by Geography
- North America
- Rest of Europe
- Asia Pacific (APAC)
- Rest of APAC
- Latin America (LATAM)
- Rest of LATAM
- Middle East & Africa (MEA)
- South Africa
- Saudi Arabia
- Rest of MEA
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact